Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells by Liu, Guizhong et al.
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 185 No. 1  67–75
www.jcb.org/cgi/doi/10.1083/jcb.200810137 JCB 67
JCB: REPORT
Correspondence to Stuart A. Aaronson: stuart.aaronson@mssm.edu
Abbreviations used in this paper: CM, conditioned medium; dnTCF4, dominant-
negative TCF4; ERK, extracellular receptor-dependent kinase; HA, hydroxy-
apatite; hMSC, human MSC; MSC, mesenchymal stem cell; Osx, osterix; PCNA, 
proliferating cell nuclear antigen; shRNA, short hairpin RNA; TCF, T cell factor; 
TCP, tri-Ca phosphate.
Introduction
Growing evidence indicates that Wnt signaling plays a critical 
role in stem/progenitor self-renewal in adult tissues (Reya and 
Clevers, 2005), in which these cells serve as reservoirs for tissue 
renewal in response to trauma, disease, and aging. In the 
canonical pathway, Wnts signal through frizzled and LRP5/6 co-
receptors, leading to inactivation of the axin–GSK3- complex, 
which otherwise phosphorylates and directs degradation of   
-catenin. Stabilized -catenin translocates into the nucleus and 
forms a complex with T cell factor (TCF)/lymphoid enhancer-
binding factor transcription factors to activate Wnt target genes 
(Reya and Clevers, 2005). Some Wnts lack this ability and stim-
ulate noncanonical pathways through effectors including JNK, 
Rho GTPase, or Ca
2+ (Veeman et al., 2003).
Adult mesenchymal stem cells (MSCs) isolated from bone 
marrow are multipotent and give rise to tissues, including bone, 
cartilage, muscle, and adipose (Pittenger et al., 1999). Recent 
studies have revealed critical transcription factors involved in the 
commitments of different MSC-derived lineages (for review see 
Harada and Rodan, 2003). For example, osteoblastic differentia-
tion is controlled by Runx2, osterix (Osx), and Dlx5, whereas 
PPAR- is involved in adipocyte commitment (for review see 
Harada and Rodan, 2003). Genetic studies have also established 
that Wnt/-catenin activity is essential for normal osteogenesis 
(Day et al., 2005; Hill et al., 2005). Enhancement of Wnt signal-
ing either by Wnt overexpression (Bennett et al., 2007) or defi-
ciency of Wnt antagonists (Morvan et al., 2006; ten Dijke et al., 
2008) is associated with increased bone formation in mice and 
humans. Loss or gain of function mutations in LRP5 also cause 
osteoporosis or high bone mass phenotypes, respectively (Gong 
et al., 2001; Boyden et al., 2002; Little et al., 2002).
The in vitro effects of Wnt signaling on osteogenic differen-
tiation of MSCs are controversial. Wnt/-catenin signaling has 
been reported to stimulate differentiation of mouse MSCs toward 
the osteoblastic lineage (Gong et al., 2001; Gaur et al., 2005). How-
ever, both stimulatory (Gregory et al., 2005) and inhibitory (Boland 
et al., 2004; de Boer et al., 2004) effects of canonical Wnt signaling 
on osteogenic differentiation by human MSCs (hMSCs) have been 
observed. Because of their osteogenic potential, human adult bone 
marrow MSCs are one of the most promising stem cell populations 
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with Wnt3a at both 5 and 25 ng/ml resulted in a significant   
relative increase in osteogenic differentiation, as manifested 
by increased AP activity and mineralization (Fig. 1, H and I). 
At 100 ng/ml, Wnt3a partially inhibited osteogenic differentia-
tion as well (Fig. 1, H and I). These results indicate that under 
conditions permissive for binary lineage differentiation, differ-
ences in sensitivity to Wnt inhibition may alter the equilibrium 
and shift the commitment from adipocytes toward osteoblasts.
One  mechanism  underlying  osteogenic  inhibition  by 
Wnt/-catenin signaling has been attributed to direct interaction 
and inhibition of Runx2 transcriptional activity by the -catenin–
Lef1 complex (Kahler and Westendorf, 2003). However, it was 
also reported that Wnt/-catenin signaling increases Runx2 level 
in mouse mesenchymal cells (Gaur et al., 2005). Thus, we exam-
ined the expression of osteoblastic transcription factors, includ-
ing Runx2, Osx, and Dlx5, in hMSCs. As shown in Fig. 2 A, the 
expression levels of these genes were reduced in Wnt1-express-
ing hMSCs in basal medium as well as under osteogenic condi-
tions compared with that in vector cells, which is consistent with 
high levels of Wnt signaling acting to down-regulate these osteo-
blastic transcription factors.
Extracellular  receptor-dependent  kinase  (ERK)  and  p38 
MAPK pathways have been shown to play critical roles in osteo-
genesis (Kratchmarova et al., 2005). As shown in Fig. 2 B, p38 
and ERK as well as JNK were activated, as indicated by their in-
creased phosphorylation in hMSCs undergoing osteogenic differ-
entiation. Activation of p38 was detectable as early as 2 d, whereas 
increased phosphorylated JNK (p-JNK) was obvious by 6 d. Wnt1 
expression largely inhibited activation of both kinases under   
osteogenic conditions, whereas there was no significant change in 
p-ERK levels in response to Wnt1 expression under the same con-
ditions (Fig. 2 B).
The Ror2 receptor tyrosine kinase plays an important role in 
skeletal development as well as mediates Wnt5a signaling to the 
JNK pathway (Oishi et al., 2003). Other studies have shown that 
Wnt5a stimulates osteogenic differentiation (Baksh et al., 2007) and 
Ror2 short hairpin RNA (shRNA) inhibits hMSC osteogenic differ-
entiation (Liu et al., 2007). When we examined Ror2 expression in 
response to osteogenic stimulation, we observed an increase, which 
was blocked by exogenous Wnt1 (Fig. 2 C). Moreover, when we in-
hibited Ror2 expression with shRNA under osteogenic conditions, 
neither p38 nor ERK activation was affected, whereas JNK activa-
tion was effectively blocked (Fig. 2 D), and osteogenic differen-
tiation was partially inhibited as well (not depicted). Similarly, 
treatment of hMSCs under differentiation conditions with SP600125, 
a small molecule inhibitor of JNK, partially inhibited osteogenic 
differentiation (Fig. 2 E). These findings support the idea that ca-
nonical Wnt inhibition of Ror2 up-regulation and JNK activation 
contributes to its osteogenic inhibitory functions.
Canonical Wnt signaling has been implicated in stem/
progenitor cell maintenance in several adult tissues (Reya and 
Clevers, 2005). Thus, we asked whether hMSCs demonstrated 
endogenous Wnt signaling activity. Using a lentiviral-based TCF 
luciferase reporter system, hMSCs showed an approximately 
sevenfold TCF reporter activity over that of the control reporter, 
and this activity could be completely inhibited by dnTCF4 expres-
sion (Fig. 3 A). We observed further that endogenous TCF activity 
for bone regeneration as well as repairing critical-size bone defects 
that fail to undergo spontaneous healing (Meijer et al., 2007). Thus, 
these experiments were undertaken in an effort to better define how 
Wnts influence hMSC commitment along osteoblastic and other 
lineages as well as the mechanisms involved.
Results and discussion
We first analyzed the in vitro biological effects of canonical Wnts 
on differentiation of adult hMSCs. Consistent with previous studies 
(Boland et al., 2004; de Boer et al., 2004), treatment of hMSCs 
with Wnt3a conditioned medium (CM) or lentiviral-mediated 
transduction of Wnt1 strongly inhibited osteogenic differentiation 
compared with that of respective control cultures, as reflected by 
reduced staining for the early osteoblastic marker AP and reduced 
mineralization as detected by Alizarin red staining (Fig. S1 A). 
Moreover, exogenous Wnt1 resulted in dramatic down-regulation 
of expression of several markers associated with osteoblastic dif-
ferentiation (for review see Harada and Rodan, 2003), including 
AP, bone sialoprotein, and osteocalcin (Fig. S1 B).
In addition to its inhibition of osteogenic differentiation, 
Wnt stimulation was associated with increased cell prolifera-
tion (Fig. S1 C). Because terminal differentiation is commonly 
associated with exit from the cell cycle, we asked whether Wnt 
inhibition of differentiation might be caused by enhanced pro-
liferation blocking exit from cell cycle. However, PDGF, which 
also increased hMSC proliferation and resulted in higher satura-
tion density (Fig. S1 C), did not inhibit osteogenic differentia-
tion, arguing that the Wnt effects could not be explained by 
stimulation of cell proliferation alone.
The  osteogenic  inhibitory  function  of  canonical  Wnts 
seemed inconsistent with the fact that this pathway plays a posi-
tive role in bone homeostasis in vivo. It has been observed that 
aging leads to a decrease of bone-forming osteoblasts and an 
increase of marrow adipocytes (Verma et al., 2002). These find-
ings are consistent with the possibility that alterations in hMSC 
lineage differentiation may have profound effects on bone for-
mation. Because Wnt signaling can also inhibit adipogenic dif-
ferentiation (Ross et al., 2000), we asked whether canonical Wnts 
might modify hMSC lineage commitment to favor osteoblastic 
differentiation. As shown in Fig. 1 (A and B), osteogenic differ-
entiation was partially inhibited at 100 ng/ml Wnt3a, whereas 
concentrations of 25 ng/ml or lower failed to detectably inhibit 
either AP activity or mineralization. In contrast, Wnt3a was much 
more potent in inhibiting adipocyte differentiation, with 40% in-
hibition observed at 5 ng/ml and complete inhibition at observed   
at 100 ng/ml (Fig. 1 C). As might be expected for transcriptional 
signaling through Wnt/-catenin, a dominant-negative TCF4 
(dnTCF4) antagonized exogenous Wnt1-mediated inhibition of 
both osteogenic and adipogenic differentiation (Fig. S1 D).
To directly compare hMSC sensitivity to Wnt inhibition 
of commitment with the osteogenic versus adipogenic lineage 
under the same conditions, we cultured these cells in a binary 
differentiation medium that efficiently induced differentiation 
along both lineages. Wnt3a significantly blocked adipogenic 
differentiation at 5 ng/ml and completely abolished adipogen-
esis at 100 ng/ml (Fig. 1, D–G and I). In marked contrast, treatment 69 FUNCTIONS OF WNT IN OSTEOGENESIS • Liu et al.
adipocyte commitment both in basal medium (Fig. S2 B) and   
under osteogenic conditions (Fig. S2 D), neither of which responses 
were observed in vector hMSCs (not depicted). All of these re-
sults argue that endogenous Wnt signaling plays an important 
role in maintaining hMSCs in a relatively undifferentiated state.
To investigate how canonical Wnt inhibitory effects on 
osteogenic differentiation in vitro might translate into a positive 
function in bone formation in vivo, we used an established ec-
topic bone formation model in immunodeficient mice (Krebsbach 
et al., 1997). When mixed with ceramic powder of hydroxy-
apatite (HA)/tri-Ca phosphate (TCP), vector-expressing hMSCs 
formed detectable small fragments of ectopic bone constituting 
1% of the total scaffold area (Fig. 4, A and G). Consistent with 
the inhibitory effects of high Wnt signaling levels on hMSC 
osteogenic differentiation in vitro, exogenous Wnt1-expressing 
hMSCs exhibited little if any detectable bone forming capac-
ity under the same conditions (Fig. 4, B and G). Based on our 
in hMSCs was heterogeneous, as only 5% of cells exhibited high 
activity using a GFP-based reporter system (Fig. 3 B). Moreover, 
this endogenous Wnt signaling was down-regulated during osteo-
genic differentiation as monitored by decreased levels of TCF re-
porter activity and expression of a known -catenin target gene, 
Axin2 (Fig. 3 C). In contrast, expression of the Wnt antagonist Dkk1 
was markedly increased during osteogenic differentiation (Fig. 3 C), 
suggesting that Dkk1 may participate in down-regulating endog-
enous Wnt signaling during osteogenic differentiation.
To assess the biological effects of endogenous Wnt signal-
ing, we compared the differentiation responses of dnTCF4 and 
vector-expressing hMSCs. In contrast to the osteogenic inhibition 
by exogenous Wnt1, dnTCF4 enhanced osteogenic differentia-
tion (Fig. 3 D), as well as increased expression of genes associ-
ated with osteogenic differentiation (Fig. S3 A). dnTCF4 also 
enhanced adipogenic differentiation (Fig. S2 B) and increased 
PPAR- expression (Fig. S2 C), with evidence of spontaneous 
Figure 1.  Differential sensitivity of hMSCs to Wnt inhibition of osteogenic versus adipogenic differentiation. (A) Scanned images of AP (top) or Alizarin 
red staining (bottom) in hMSCs after 3 wk in osteogenic medium (OS) in the presence of different concentrations (in nanograms/milliliter) of recombinant 
Wnt3a. (B) Relative AP activity and Ca deposition under conditions as in A. Undif, undifferentiated. (C) Quantification of adipocyte differentiation in re-
sponse to Wnt3a. Bars represent relative extracted Oil red O staining after 3 wk in adipogenic medium. (D–G) AP and Oil red O staining in hMSCs after   
3 wk in a mixed medium containing equal volumes of osteogenic and adipogenic media. Wnt3a was added at 0 (D), 5 (E), 25 (F), or 100 ng/ml (G). (H) Relative 
AP activity in hMSC cultures as in D–G. (I) Relative extracted Oil red O staining and Ca deposition in hMSC cultures as in D–G. (B, C, H, and I) Results 
represent mean values ± SD from two independent experiments performed in triplicate. *, P < 0.05. Bar, 20 µm.JCB • VOLUME 185 • NUMBER 1 • 2009   70
that Wnt1-expressing hMSCs act primarily to stimulate osteo-
genesis by Wnt1-negative hMSCs.
Next, we examined the Wnt signaling activity in mixed 
implants by immunostaining for -catenin because the presence 
of nonmembrane-bound -catenin is a hallmark of canonical 
Wnt signaling activation. As shown in Fig. 5 G, cytoplasmic 
-catenin was apparent within both LacZ-positive (hMSC-LacZ) 
and -negative (hMSC-Wnt1) cells surrounding bone-like struc-
tures but was generally undetectable in osteocytes embedded 
within the ectopic bone. These findings argue that only hMSCs 
with low Wnt signaling activity are capable of differentiating 
into bone-forming osteocytes.
Immunostaining  for  proliferating  cell  nuclear  antigen 
(PCNA) revealed significant increases in both LacZ- and Wnt1-
expressing hMSCs in mixed implants (Fig. 5, H–J) compared 
with hMSC-LacZ cells alone (Fig. 5 J and Fig. S3 D). These 
observations  of  heterogeneous  endogenous  Wnt  activity  in   
hMSCs, we sought to model higher levels of heterogeneous 
Wnt activity by mixing vector and Wnt1-expressing hMSCs   
at different ratios in the implants. These conditions led to a 
striking enhancement of bone formation with as much as 25% 
bone formation observed (Fig. 4, C–G).
To directly identify which cell population was responsible, 
we  labeled  hMSCs  with  LacZ  by  viral  transduction.  LacZ- 
expressing hMSCs alone formed only small amounts of bone 
(Fig. S3 A), which is similar to that observed with vector hMSCs 
(Fig. 4 A). When bone formation was significantly enhanced in 
implants with mixed LacZ- and Wnt1-expressing hMSCs (Fig. S3, 
B and C), the bone structures were predominately comprised   
of LacZ-staining cells. In contrast, Wnt1 immunostaining was   
observed  in  dense  cell  clusters  surrounding  bone  structures   
(Fig. 5, A–F). These results strongly support the conclusion 
Figure 2.  Mechanisms involved in Wnt inhibition of osteogenic differentiation. (A) Real-time PCR analysis of Runx2, Osx, and Dlx5 expression in vector 
(Vec)- or Wnt1-expressing hMSCs grown in basal (Undiff) or osteogenic medium for 4 and 14 d. Results represent mean values ± SD from two independent 
experiments performed in triplicate. *, P < 0.05. (B and C) Representative immunoblots for MAPK activation (B) and Ror2 expression (C) in vector- or Wnt1-
expressing hMSCs grown in basal or osteogenic medium (OS) for 2 and 6 d. (D) Immunoblots of MAPK activation in control or Ror2 shRNA–expressing   
hMSCs grown as in B. (E) Scanned images of AP and Alizarin red staining in hMSCs after osteogenic induction in the presence or absence of   
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Based on our present findings and the aforementioned 
previous studies, we propose a model for canonical Wnt modu-
lation of osteogenesis by hMSCs in vivo (Fig. 5 L) in which a 
Wnt activity gradient results from the asymmetrical localiza-
tion of Wnts and antagonists between hMSC stem/progenitor 
and osteoblasts/osteocyte compartments. For example, we ob-
served Dkk1 up-regulation during osteogenesis, and previous 
studies have indicated increased expression of other Wnt antag-
onists, secreted frizzled-related proteins (Boland et al., 2004), 
and sclerostin by osteoblasts/osteocytes (Winkler et al., 2003). 
Such a gradient of Wnt activity likely plays important roles in 
stimulating self-renewal and expansion of hMSCs/progenitors 
at high Wnt activity levels while permitting osteoblastic differ-
entiation where Wnt activity decreases. Differential sensitivity 
to Wnt inhibition of osteogenesis versus adipogenesis in vitro 
also provides a possible mechanism to favor osteoblastic com-
mitment within a certain range of Wnt activity by restricting 
hMSCs from adopting adipocytic cell fate. Our findings strongly 
favor a direct role of canonical Wnt in bone formation but do 
not exclude a role for LRP5 on bone formation through regu-
lation of the hormonal acting serotonin as recently reported 
(Yadav et al., 2008).
Despite their potential clinical use in regenerative medicine 
and tissue engineering, bone formation by hMSCs is poor, and, 
so far, repair of critical-size bone defects has not been achieved 
results correlated with the increased numbers of both Wnt1- and 
LacZ-staining cells observed in mixed implants (Fig. 5 K). These 
results establish that canonical Wnt1 specifically stimulated in 
vivo proliferation of hMSCs in both autocrine and paracrine 
modes, with the latter increasing the population of naive hMSCs 
capable of undergoing osteogenesis under low or undetectable 
Wnt signaling.
To address whether or not the enhanced bone formation by 
Wnt1 was caused by other factors induced by activated -catenin 
signaling, we expressed stabilized mutant -catenin in hMSCs 
and examined the effects on bone formation in vivo. -Catenin 
was specifically detected in hMSCs expressing stabilized -catenin 
but not in mixed LacZ-expressing hMSCs in the same implants 
(Fig. S3 E) or implants with hMSC-LacZ cells alone (Fig. S3 F). 
Of  note,  expression  of  stabilized  -catenin  significantly  in-
creased cell numbers in implants but had relatively little effect 
on the number of naive hMSC-LacZ cells under mixed condi-
tions (Fig. S3 G). Consistent with the in vitro osteogenic inhibi-
tory function of -catenin reported previously (Jian et al., 2006), 
we observed little if any bone formation by hMSCs express-
ing mutant -catenin alone and no increased bone formation 
when mixed with hMSC-LacZ cells (Fig. S3 H). These re-
sults establish that canonical Wnt ligands acting in a cell-
nonautonomous  manner  are  required  for  enhanced  bone 
formation in this context.
Figure 3.  Functions of endogenous Wnt signaling in hMSC osteogenic differentiation. (A) TCF reporter analysis in hMSCs after infection with Top or Fop 
luciferase virus and Renilla luciferase virus together with either vector (Vec) or dnTCF4 virus. Luciferase activity was measured at 48 h and normalized to 
Renilla activity. (B) Parental or Wnt1-expressing hMSCs were transduced with Top- or Fop-GFP virus, and parental cells were treated at 24 h with or without 
Wnt3a CM. GFP was visualized by fluorescence microscopy at 72 h. (C) Top luciferase reporter activity (left) and Axin2 and Dkk1 expression by real-time 
PCR (right) in hMSCs at 14 d in osteogenic medium. Fold changes were all relative to levels in undifferentiated (Undiff) cells. *, P < 0.05. (D) Scanned   
images of AP or Alizarin red staining (left) in hMSCs expressing vector or dnTCF4 after 3 wk in osteogenic medium. Quantification of relative AP activity and 
Ca content is shown (right). (A, C, and D) Results represent mean values ± SD from two independent experiments performed in triplicate. Bars, 10 µm.JCB • VOLUME 185 • NUMBER 1 • 2009   72
Materials and methods
Cell culture, CM, growth factors, and inhibitors
Primary  hMSC  cultures  were  obtained  from  three  independent  donors 
(Lonza) and expanded in basal medium or induced with osteogenic or   
adipogenic medium (Lonza) according to the manufacturer’s instructions. CM 
of control or Wnt3a was collected from L-cell transfectant as described previ-
ously (Boland et al., 2004). Recombinant Wnt3a (R&D Systems), PDGF-BB 
(PeproTech), and SP600125 (EMD) were commercially obtained.
Assays for in vitro osteogenic and adipogenic differentiation
Ca  deposition  was  analyzed  by  staining  with  2%  Alizarin  red  (Sigma- 
Aldrich) or extracted with 0.5 N HCl and quantified with Liquicolor kit (Stan-
Bio  Laboratory).  AP  activity  was  detected  histochemically  with  Leukocyte 
(Meijer et al., 2007). A recent study showed that preexposure of 
hMSCs to dibutyryl-cAMP, an activator of the PKA pathway, can 
enhance ectopic bone formation by these cells from 1.5% in the 
control group up to 6% (Siddappa et al., 2008). Our present find-
ings indicate that canonical Wnts can have a major positive im-
pact on hMSC-mediated bone formation in HA/TCP transplants, 
increasing bone formation up to 25% under our experimental 
conditions. The appropriate manipulation of Wnt ligand expres-
sion might lead to significant improvement in the efficiency of 
tissue engineering and enhance the therapeutic value of these 
stem cells for the restoration of bone defects.
Figure  4.  Effects  of  canonical  Wnt  signaling 
on osteogenesis by hMSCs in an ectopic bone 
formation model. (A–F) hMSC-vector cells alone 
(A), hMSC-Wnt1 cells alone (B), or hMSC-vector 
cells mixed with hMSC-Wnt1 cells (C–F) at ratio 
of 1:1 (C), 3:1 (D), 10:1 (E), or 20:1 (F). b, bone;   
HA, HA/TCP. Arrows designate osteocytes within   
bone structures in eosin-stained sections. (G) Quan-
titative analysis of bone formation by hMSCs in 
the recovered implants of A–F. Results represent 
mean values ± SD from experiments performed 
in triplicate. Bars, 100 µm.73 FUNCTIONS OF WNT IN OSTEOGENESIS • Liu et al.
Figure 5.  Canonical Wnt1 stimulates bone formation by hMSCs in a paracrine mode in vivo. (A–C) hMSC-Wnt1 alone (A) or hMSC-LacZ mixed with 
hMSC-Wnt1 (B and C) at ratio of 1:1 (B) or 3:1 (C). Sections in A–C were stained for Wnt1 protein (brown) and LacZ (blue), with higher magnifica-
tion images shown in D–F as indicated. Dashed lines outline bone. Red arrowheads indicate LacZ-positive osteocytes. (G) -Catenin staining (brown) 
in section with 1:1 mixture as in B. Black arrows indicate Wnt1 cells, and red arrows indicate LacZ cells with positive -catenin staining. (H) A section 
with bone structures surrounded by mixed hMSCs as in B was stained for Wnt1 (brown), LacZ (blue), and PCNA (red), with a higher magnification 
image shown in I as indicated. Red and black arrows indicate positive PCNA staining in Wnt1- and LacZ-expressing hMSCs, respectively. All sections 
were counterstained with hematoxylin (dark blue). (J) Quantification of PCNA staining in implants with hMSC-LacZ alone or 1:1 mixed hMSCs as in B. 
(K) Quantification of cell numbers in implants of LacZ- and Wnt1-expressing hMSCs. (J and K) Numbers shown are mean values ± SD of experiments 
performed in triplicate. (L) Model for the effects of a canonical Wnt gradient on bone formation by hMSCs in vivo. sFRPs, secreted frizzled-related 
proteins; Sost, sclerostin. Bars, 100 µm.JCB • VOLUME 185 • NUMBER 1 • 2009   74
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